Folliculin Explained

The tumor suppressor gene FLCN encodes the protein folliculin, also known as Birt–Hogg–Dubé syndrome protein, which functions as an inhibitor of Lactate Dehydrogenase-A and a regulator of the Warburg effect.[1] Folliculin (FLCN) is also associated with Birt–Hogg–Dubé syndrome, which is an autosomal dominant inherited cancer syndrome in which affected individuals are at risk for the development of benign cutaneous tumors (folliculomas), pulmonary cysts (often associated with pneumothorax), and kidney tumors.[2]

Gene

Structure

The FLCN gene consists of 14 exons.[3]

Location

Cytogenetic location: The FLCN gene is located on the short (p) arm of chromosome 17 at position 11.2. (17p11.2).[4]

Molecular location on chromosome 17: base pairs 17,056,252 to 17,081,230 (NCI Build 36.1)

Clinical significance

Germline mutations in the FLCN gene cause Birt–Hogg–Dubé syndrome (BHD), an autosomal dominant disease that predisposes individuals to develop benign tumors of the hair follicle called fibrofolliculomas, lung cysts, spontaneous pneumothorax, and an increased risk for kidney tumors. FLCN mutations have also been found in the germline of patients with inherited spontaneous pneumothorax and no other clinical manifestations.[5] [6]

In a risk assessment performed in affected and unaffected members of BHD families, the odds ratio for developing kidney tumors in a person affected with BHD was 6.9 times greater than his unaffected siblings. The odds ratio for spontaneous pneumothorax in BHD affected individuals, when adjusted for age, was 50.3 times greater than unaffected family members.[7]

Discovery

Birt–Hogg–Dubé syndrome was originally described by three Canadian physicians in a family in which 15 of 70 members over 3 generations exhibited a triad of dermatological lesions (fibrofolliculomas, trichodiscomas and acrochordons).[8] Subsequently, cosegregation of kidney neoplasms with BHD cutaneous lesions was observed in 3 families with a family history of kidney tumors,[9] suggesting that kidney tumors may be part of the BHD syndrome phenotype. In order to identify the genetic locus for BHD syndrome, genetic linkage analysis was performed in families recruited on the basis of BHD cutaneous lesions.[10] [11] A region spanning chromosome 17p11 was identified and mutations in a novel gene, FLCN, were subsequently found in the germline of individuals affected with BHD syndrome.

Genetics

The FLCN gene encodes a 64 kDa protein, FLCN, which is highly conserved across species. The majority of germline FLCN mutations identified in BHD patients are loss-of-function mutations including frameshift mutations (insertion/deletion), nonsense mutations, and splice site mutations that are predicted to inactivate the FLCN protein, although some missense mutations have been reported that exchange one nucleotide for another and consequently result in a different amino acid at the mutation site.[12] Most mutations are identified by DNA sequencing. With the advent of multiplex ligation-dependent probe amplification (MLPA) technology, partial deletions of the FLCN gene have also been identified[13] [14] permitting a FLCN mutation detection rate in BHD cohorts that approaches 90%. Very few FLCN mutations have been found in association with sporadic kidney tumors indicating that FLCN mutation may play only a minor role in non-inherited kidney cancer.[15] [16] [17]

Experimental evidence supports a role for FLCN as a tumor suppressor gene. In BHD-associated kidney tumors, the inherited FLCN gene with a germline mutation is present in all cells, but the remaining wild type copy is inactivated in the tumor cells through somatic mutation or loss of heterozygosity.[18] Naturally-occurring dog and rat models with germline Flcn mutations develop kidney tumors that retain only the mutant copy of the gene.[19] [20] Homozygous inactivation of Flcn in these animal models is lethal to the embryo. Tumors develop in mice injected with FLCN-deficient kidney cancer cells from BHD-associated human tumors but when wild type FLCN is restored in these cells, tumor development is inhibited.[21] Additionally, injection of kidney tumor cells from the adenocarcinoma cell line ACHN with FLCN inactivation into immunocompromised mice resulted in the growth of significantly larger tumors, further underscoring a tumor suppressor role for FLCN.[22] Based on the presence of FLCN staining by immunohistochemistry, haploinsufficiency, that is mutation of one copy of FLCN with retention of the wild type copy, may be sufficient for the development of fibrofolliculomas[23] and lung cysts.[24]

Function

Interactions

FLCN has been shown to interact through its C-terminus with two new co-chaperones folliculin interacting protein 1 (FNIP1)[25] [26] and folliculin interacting protein 2 (FNIP2/FNIPL),[27] and indirectly through FNIP1 and FNIP2 with AMP-activated protein kinase (AMPK). AMPK is an important energy sensor in cells and negative regulator of mechanistic target of rapamycin (mTOR)[28] suggesting that FLCN and FNIP1 may play a role in modulating mTOR activity through energy- or nutrient-sensing pathways. Coimmunoprecipitation experiments with FNIPL/FNIP2 and FLCN expressed in Cos7 cells have shown that the C-termini of FLCN and FNIPL/FNIP2 are required for optimal FLCN-FNIPL binding.[27] In the absence of either FNIP1 or FNIPL/FNIP2 expression, FLCN localizes to the nucleus, while co-expressed FLCN and FNIPL colocalize to the cytoplasm in a reticular pattern.[27]

FLCN phosphorylation

FLCN phosphorylation was diminished by rapamycin and amino acid starvation and facilitated by FNIP1 overexpression, suggesting that FLCN phosphorylation may be regulated by mTOR and AMPK signaling. FNIP1 was phosphorylated by AMPK and its phosphorylation was inhibited in a dose-dependent manner by an AMPK inhibitor, resulting in reduced FNIP1 expression.FLCN has multiple phosphorylation sites including serine 62, which are differentially affected by FNIP1 binding and by inhibitors of mTOR and AMPK.[29] The significance of this modification, however, is unknown.

Functions of FLCN

Folliculin (FLCN) functions as a binding partner and uncompetitive inhibitor of Lactate Dehydrogenase-A (LDHA). A flexible loop within the amino-terminus of FLCN controls movement of the LDHA active site loop, tightly regulating its enzyme activity and, consequently, metabolic homeostasis in normal cells. Cancer cells that experience the Warburg effect show FLCN dissociation from LDHA. Treatment of these cells with a decapeptide derived from the FLCN loop region causes cell death. The glycolytic shift of cancer cells seems to be the result of FLCN inactivation or dissociation from LDHA. FLCN-mediated inhibition of LDHA provides a new paradigm for the regulation of glycolysis.

Several pathways in which FLCN plays a role as a tumor suppressor have been identified, but it remains to be determined which of these pathways, when dysregulated, leads to the cutaneous, lung and kidney phenotypes associated with Birt-Hogg-Dubé syndrome.

Regulation of the AKT-mTOR pathway

Work with Flcn-deficient mouse models suggests a role for FLCN in regulating the AKT-mechanistic target of rapamycin (mTOR) signaling pathway, but the results are conflicting. mTOR activation was seen in the highly cystic kidneys that developed in mice with kidney-targeted inactivation of Flcn.[30] [31] Elevated AKT and phospho-AKT proteins, and activation of mTORC1 and mTORC2 were observed in late-onset tumors that developed in aged Flcn heterozygous mice subsequent to loss of the remaining Flcn wild type allele, and in FLCN-deficient kidney tumors from BHD patients.[32] On the other hand, mTOR inhibition was demonstrated in smaller cysts (although mTOR activation was seen in larger cysts) that developed in Flcn heterozygous knockout mice generated with a gene trapping approach.[22] N-ethyl-N-nitrosourea (ENU) mutagenesis of another Flcn heterozygous mouse model produced tumors with reduced mTOR activity.[33] Evidence from studies in yeast suggests that the FLCN ortholog Bhd activates the mTOR ortholog Tor2.[34] These opposing effects of FLCN deficiency on the mTOR pathway have led to the hypothesis that FLCN regulation of mTOR activity may be context or cell-type dependent.

mTORC1 activation on the lysosome

Resolution of the crystal structure of the FLCN carboxy-terminal protein domain revealed a structural similarity to the differentially expressed in normal cells and neoplasia (DENN) domain of DENN1B suggesting that they are distantly related proteins. The DENN domain family of proteins are guanine nucleotide exchange factors (GEFs) for Rab proteins, members of the Ras superfamily of G proteins that are involved in vesicular transport suggesting that FLCN may have a similar function.[35]

FLCN acts as a GTPase-activating protein (GAP) toward Rag C/D GTPases, members of another Ras-related GTP-binding protein family, which are necessary for amino acid-dependent mTORC1 activation at the lysosomal membrane.[36] The heterodimeric Rag GTPases (RagA or B in complex with RagC or D) in a lysosome-associated complex with Ragulator and vacuolar adenosine triphosphatase (v-ATPase) interact with mTORC1 in response to amino acids from the lysosomal lumen to promote translocation of mTORC1 to the lysosomal surface for activation by the small GTPase Ras-homolog enriched in brain (Rheb). GTP-loading of RagA/B is a requirement for amino acid signaling to mTORC1.[37] In recent studies, FLCN was shown to localize to the lysosome surface under amino acid starved conditions, where with its binding partners FNIP1/FNIP2, FLCN acts as a GAP to facilitate GDP-loading of Rag C/D, clarifying the role of this Rag GTPase in amino acid-dependent mTORC1 activation. Another report demonstrated that FLCN in association with FNIP1 preferentially binds to GDP-bound /nucleotide free Rag A/B under amino acid deprived conditions suggesting a potential role for FLCN as a GEF for RagA/B.[38] Recently the heterodimeric Lst4-Lst7 complex in yeast, orthologous to the mammalian FLCN-FNIP1 complex, was found to function as a GAP for Gtr2, the yeast ortholog of Rag C/D, and cluster at the vacuolar membrane in amino acid starved cells. Refeeding of amino acids stimulated Lst4-Lst7 binding to and GAP activity towards Gtr2 resulting in mTORC1 activation and demonstrating conservation of a GAP function for FLCN in lower organisms.[39]

Control of TFE3/TFEB transcriptional activation

TFE3 and TFEB are members of the microphthalmia-associated transcription factor (MiTF) family, which also includes MiTF and TFEC. Gene fusions of TFE3 with a number of different gene partners can arise sporadically and are responsible for Xp11.2 translocation renal cell carcinoma.[40] FLCN-deficient BHD associated renal tumors and tumors that develop in mouse models with Flcn inactivation were found to have elevated expression of transmembrane glycoprotein NMB (GPNMB), a transcriptional target of TFE3.[41] Subsequently, FLCN was shown to regulate TFE3 activity by sequestering TFE3 in the cytoplasm where it is transcriptionally inactive; however, loss of FLCN expression results in localization of TFE3 to the nucleus driving transcriptional activation of its target genes including GPNMB. Another study investigating genes required for mouse embryonic stem cell (ESC) progression from pluripotency to cell lineage differentiation revealed that Flcn in complex with Fnip1/2 was necessary for ESC exit from pluripotency through cytoplasmic sequestering of Tfe3, thereby abrogating expression of its gene target, estrogen-related receptor beta(Esrrb), the core pluripotency factor.[42]

Regulation of PGC-1α and mitochondrial biogenesis

Chromophobe renal carcinoma and hybrid oncocytic tumors with features of chromophobe renal carcinoma and renal oncocytoma, which are the most common renal tumor histologic subtypes associated with BHD, contain large numbers of mitochondria. Comparative gene expression profiling of BHD-associated renal tumors and sporadic counterpart tumors revealed distinct gene expression patterns and cytogenetic differences between the groups. BHD-associated tumors displayed high expression of mitochondrial- and oxidative phosphorylation-associated genes reflecting deregulation of the peroxisome proliferator-activated receptor gamma coactivator 1-alpha / mitochondrial transcription factor A (PGC-1α/TFAM) signaling axis.[43] FLCN expression was inversely correlated with PGC-1α activation, which drives mitochondrial biogenesis. In support of these data, FLCN inactivation was correlated with PGC-1α activation and upregulation of its target genes in BHD-associated renal tumors, and kidney, heart and muscle tissues from genetically engineered mouse models with Flcn inactivation targeted to the respective tissues.[44] [45]

Maintenance of cell-cell adhesions and regulation of RhoA signaling

Yeast two-hybrid screening performed by two independent groups identified p0071 (plakophilin-4) as a FLCN interacting protein.[46] [47] p0071 binds E-cadherin at adherens junctions, which are important for maintenance of cell architecture in epithelial tissues, and regulates RhoA activity. Loss of FLCN function leads to a disruptive effect on cell-cell adhesions and cell polarity, and dysregulation of RhoA signaling. Additional supporting evidence includes reduction in E-cadherin expression and increased alveolar apoptosis in lungs from lung-targeted Flcn-deficient mice,[48] and increased cell-cell adhesions in FLCN-deficient lung cell lines.[49] These studies suggest a potential function of FLCN in maintaining proper cell-cell adhesions for lung cell integrity and support the "stretch hypothesis" as a mechanism of pulmonary cyst pathogenesis in BHD.[50]

Ciliogenesis and cilia-dependent flow sensory mechanisms

Individuals affected with the inherited kidney cancer syndromes von Hippel–Lindau syndrome and tuberous sclerosis complex can develop kidney cysts in addition to kidney tumors, which have been shown to result from defects in primary cilia function.[51] [52] BHD patients also may present with kidney cysts, which led researchers to investigate a potential role for FLCN in regulating primary cilia development and/or function. FLCN protein was found to localize on primary cilia, the basal body and centrosome in different cell types. FLCN siRNA knockdown in nutrient starved kidney cells resulted in delayed cilia development. Both overexpression of FLCN in FLCN-expressing kidney cells and knockdown of FLCN resulted in reduced numbers of cilia and aberrant cell divisions, suggesting that levels of FLCN must be tightly regulated for proper ciliogenesis.[53] Primary cilia play a role in inhibiting the canonical Wnt signaling pathway (Wnt/β-catenin signaling pathway) by sequestering β-catenin in the basal body, and dysregulated Wnt/β-catenin signaling has been linked to kidney cyst formation. In Flcn-deficient mouse inner medullary collecting duct cells, levels of unphosphorylated (active) β-catenin and its down stream targets were elevated suggesting that improper activation of the canonical Wnt/β-catenin signaling pathway through defective ciliogenesis may lead to kidney, and potentially lung, cyst development in BHD syndrome.

Additional experimental evidence that FLCN may be involved in primary cilium function was obtained from a yeast two-hybrid screening that identified KIF3A as a FLCN interacting protein.[54] Intraflagellar transport, which is required for primary cilium assembly and maintenance, is driven by kinesin-2 motor made up of subunits KIF3A and KIF3B. Researchers have shown that FLCN could interact with both subunits in a cilium-dependent manner and localize to cilia in FLCN-expressing but not FLCN-deficient cells. Cilia have been shown to act as flow sensors and suppress mTOR signaling by activating the serine/threonine kinase LKB1 located in the basal body of resting cells in response to flow stimuli. LKB1 in turn phosphorylates and activates AMPK, a negative regulator of mTOR activation.[55] Flow stress was able to suppress mTOR signaling in FLCN-expressing human kidney cells but not under FLCN deficient conditions, and required intact cilia. FLCN was shown to recruit LKB1 and facilitate its interaction with AMPK in the basal body in a flow stress-dependent manner. These findings suggest a role for FLCN in the mechanosensory signaling machinery of the cell that controls the cilia-dependent regulation of the LKB1-AMPK-mTOR signaling axis.

Other potential functions

Additional potential roles for FLCN in autophagy,[56] [57] [58] TGF β signaling,[59] regulation of AMPK activity,[60] [61] and regulation of HIF-1α transcriptional activity[62] have been described.

Further reading

External links

Notes and References

  1. Woodford MR, Baker-Williams AJ, Sager RA, Backe SJ, Blanden AR, Hashmi F, Kancherla P, Gori A, Loiselle DR, Castelli M, Serapian SA, Colombo G, Haystead TA, Jensen SM, Stetler-Stevenson WG, Loh SN, Schmidt LS, Linehan WM, Bah A, Bourboulia D, Bratslavsky G, Mollapour M . 6 . The tumor suppressor folliculin inhibits lactate dehydrogenase A and regulates the Warburg effect . Nature Structural & Molecular Biology . 28 . 8 . 662–670 . August 2021 . 34381247 . 10.1038/s41594-021-00633-2 . 9278990 .
  2. Linehan WM, Schmidt LS, Crooks DR, Wei D, Srinivasan R, Lang M, Ricketts CJ . The Metabolic Basis of Kidney Cancer . Cancer Discovery . 9 . 8 . 1006–1021 . August 2019 . 31088840 . 10.1158/2159-8290.CD-18-1354 . 3563773 .
  3. Nickerson ML, Warren MB, Toro JR, Matrosova V, Glenn G, Turner ML, Duray P, Merino M, Choyke P, Pavlovich CP, Sharma N, Walther M, Munroe D, Hill R, Maher E, Greenberg C, Lerman MI, Linehan WM, Zbar B, Schmidt LS . 6 . Mutations in a novel gene lead to kidney tumors, lung wall defects, and benign tumors of the hair follicle in patients with the Birt-Hogg-Dubé syndrome . Cancer Cell . 2 . 2 . 157–64 . August 2002 . 12204536 . 10.1016/S1535-6108(02)00104-6 . free .
  4. Web site: Folliculin . Genetics Home Reference . National Library of Medicine, U.S. Department of Health and Human Services .
  5. Ren HZ, Zhu CC, Yang C, Chen SL, Xie J, Hou YY, Xu ZF, Wang DJ, Mu DK, Ma DH, Wang Y, Ye MH, Ye ZR, Chen BF, Wang CG, Lin J, Qiao D, Yi L . 6 . Mutation analysis of the FLCN gene in Chinese patients with sporadic and familial isolated primary spontaneous pneumothorax . Clinical Genetics . 74 . 2 . 178–83 . August 2008 . 18505456 . 10.1111/j.1399-0004.2008.01030.x . 8393765 .
  6. Graham RB, Nolasco M, Peterlin B, Garcia CK . 29807063 . Nonsense mutations in folliculin presenting as isolated familial spontaneous pneumothorax in adults . American Journal of Respiratory and Critical Care Medicine . 172 . 1 . 39–44 . July 2005 . 15805188 . 10.1164/rccm.200501-143OC .
  7. Zbar B, Alvord WG, Glenn G, Turner M, Pavlovich CP, Schmidt L, Walther M, Choyke P, Weirich G, Hewitt SM, Duray P, Gabril F, Greenberg C, Merino MJ, Toro J, Linehan WM . 6 . Risk of renal and colonic neoplasms and spontaneous pneumothorax in the Birt-Hogg-Dubé syndrome . Cancer Epidemiology, Biomarkers & Prevention . 11 . 4 . 393–400 . April 2002 . 11927500 .
  8. Birt AR, Hogg GR, Dubé WJ . Hereditary multiple fibrofolliculomas with trichodiscomas and acrochordons . Archives of Dermatology . 113 . 12 . 1674–7 . December 1977 . 596896 . 10.1001/archderm.113.12.1674.
  9. Toro JR, Glenn G, Duray P, Darling T, Weirich G, Zbar B, Linehan M, Turner ML . Birt-Hogg-Dubé syndrome: a novel marker of kidney neoplasia . Archives of Dermatology . 135 . 10 . 1195–202 . October 1999 . 10522666 . 10.1001/archderm.135.10.1195.
  10. Schmidt LS, Warren MB, Nickerson ML, Weirich G, Matrosova V, Toro JR, Turner ML, Duray P, Merino M, Hewitt S, Pavlovich CP, Glenn G, Greenberg CR, Linehan WM, Zbar B . 6 . Birt-Hogg-Dubé syndrome, a genodermatosis associated with spontaneous pneumothorax and kidney neoplasia, maps to chromosome 17p11.2 . American Journal of Human Genetics . 69 . 4 . 876–82 . October 2001 . 11533913 . 10.1086/323744 . 1226073.
  11. Khoo SK, Bradley M, Wong FK, Hedblad MA, Nordenskjöld M, Teh BT . Birt-Hogg-Dubé syndrome: mapping of a novel hereditary neoplasia gene to chromosome 17p12-q11.2 . Oncogene . 20 . 37 . 5239–42 . August 2001 . 11526515 . 10.1038/sj.onc.1204703 . 9672228 .
  12. Toro JR, Wei MH, Glenn GM, Weinreich M, Toure O, Vocke C, Turner M, Choyke P, Merino MJ, Pinto PA, Steinberg SM, Schmidt LS, Linehan WM . 6 . BHD mutations, clinical and molecular genetic investigations of Birt-Hogg-Dubé syndrome: a new series of 50 families and a review of published reports . Journal of Medical Genetics . 45 . 6 . 321–31 . June 2008 . 18234728 . 10.1136/jmg.2007.054304 . 2564862.
  13. Benhammou JN, Vocke CD, Santani A, Schmidt LS, Baba M, Seyama K, Wu X, Korolevich S, Nathanson KL, Stolle CA, Linehan WM . 6 . Identification of intragenic deletions and duplication in the FLCN gene in Birt-Hogg-Dubé syndrome . Genes, Chromosomes & Cancer . 50 . 6 . 466–77 . June 2011 . 21412933 . 10.1002/gcc.20872 . 3075348.
  14. Kunogi M, Kurihara M, Ikegami TS, Kobayashi T, Shindo N, Kumasaka T, Gunji Y, Kikkawa M, Iwakami S, Hino O, Takahashi K, Seyama K . 6 . Clinical and genetic spectrum of Birt-Hogg-Dube syndrome patients in whom pneumothorax and/or multiple lung cysts are the presenting feature . Journal of Medical Genetics . 47 . 4 . 281–7 . April 2010 . 20413710 . 10.1136/jmg.2009.070565 . 2981024.
  15. Khoo SK, Kahnoski K, Sugimura J, Petillo D, Chen J, Shockley K, Ludlow J, Knapp R, Giraud S, Richard S, Nordenskjöld M, Teh BT . 6 . Inactivation of BHD in sporadic renal tumors . Cancer Research . 63 . 15 . 4583–7 . August 2003 . 12907635 .
  16. Murakami T, Sano F, Huang Y, Komiya A, Baba M, Osada Y, Nagashima Y, Kondo K, Nakaigawa N, Miura T, Kubota Y, Yao M, Kishida T . 44617711 . 6 . Identification and characterization of Birt-Hogg-Dubé associated renal carcinoma . The Journal of Pathology . 211 . 5 . 524–31 . April 2007 . 17323425 . 10.1002/path.2139 .
  17. Davis CF, Ricketts CJ, Wang M, Yang L, Cherniack AD, Shen H, Buhay C, Kang H, Kim SC, Fahey CC, Hacker KE, Bhanot G, Gordenin DA, Chu A, Gunaratne PH, Biehl M, Seth S, Kaipparettu BA, Bristow CA, Donehower LA, Wallen EM, Smith AB, Tickoo SK, Tamboli P, Reuter V, Schmidt LS, Hsieh JJ, Choueiri TK, Hakimi AA, Chin L, Meyerson M, Kucherlapati R, Park WY, Robertson AG, Laird PW, Henske EP, Kwiatkowski DJ, Park PJ, Morgan M, Shuch B, Muzny D, Wheeler DA, Linehan WM, Gibbs RA, Rathmell WK, Creighton CJ . 6 . The somatic genomic landscape of chromophobe renal cell carcinoma . Cancer Cell . 26 . 3 . 319–30 . September 2014 . 25155756 . 10.1016/j.ccr.2014.07.014 . 4160352.
  18. Vocke CD, Yang Y, Pavlovich CP, Schmidt LS, Nickerson ML, Torres-Cabala CA, Merino MJ, Walther MM, Zbar B, Linehan WM . 6 . High frequency of somatic frameshift BHD gene mutations in Birt-Hogg-Dubé-associated renal tumors . Journal of the National Cancer Institute . 97 . 12 . 931–5 . June 2005 . 15956655 . 10.1093/jnci/dji154 . free .
  19. Lingaas F, Comstock KE, Kirkness EF, Sørensen A, Aarskaug T, Hitte C, Nickerson ML, Moe L, Schmidt LS, Thomas R, Breen M, Galibert F, Zbar B, Ostrander EA . 6 . A mutation in the canine BHD gene is associated with hereditary multifocal renal cystadenocarcinoma and nodular dermatofibrosis in the German Shepherd dog . Human Molecular Genetics . 12 . 23 . 3043–53 . December 2003 . 14532326 . 10.1093/hmg/ddg336 .
  20. Okimoto K, Sakurai J, Kobayashi T, Mitani H, Hirayama Y, Nickerson ML, Warren MB, Zbar B, Schmidt LS, Hino O . 6 . A germ-line insertion in the Birt-Hogg-Dubé (BHD) gene gives rise to the Nihon rat model of inherited renal cancer . Proceedings of the National Academy of Sciences of the United States of America . 101 . 7 . 2023–7 . February 2004 . 14769940 . 10.1073/pnas.0308071100 . 357045. 2004PNAS..101.2023O . free .
  21. Hong SB, Oh H, Valera VA, Stull J, Ngo DT, Baba M, Merino MJ, Linehan WM, Schmidt LS . Tumor suppressor FLCN inhibits tumorigenesis of a FLCN-null renal cancer cell line and regulates expression of key molecules in TGF-beta signaling . Molecular Cancer . 9 . 160 . June 2010 . 20573232 . 10.1186/1476-4598-9-160 . 2907329 . free .
  22. Hudon V, Sabourin S, Dydensborg AB, Kottis V, Ghazi A, Paquet M, Crosby K, Pomerleau V, Uetani N, Pause A . 6 . Renal tumour suppressor function of the Birt-Hogg-Dubé syndrome gene product folliculin . Journal of Medical Genetics . 47 . 3 . 182–9 . March 2010 . 19843504 . 10.1136/jmg.2009.072009 . 24687473 .
  23. van Steensel MA, Verstraeten VL, Frank J, Kelleners-Smeets NW, Poblete-Gutiérrez P, Marcus-Soekarman D, Bladergroen RS, Steijlen PM, van Geel M . 6 . Novel mutations in the BHD gene and absence of loss of heterozygosity in fibrofolliculomas of Birt-Hogg-Dubé patients . The Journal of Investigative Dermatology . 127 . 3 . 588–93 . March 2007 . 17124507 . 10.1038/sj.jid.5700592 . free .
  24. Koga S, Furuya M, Takahashi Y, Tanaka R, Yamaguchi A, Yasufuku K, Hiroshima K, Kurihara M, Yoshino I, Aoki I, Nakatani Y . 20769705 . 6 . Lung cysts in Birt-Hogg-Dubé syndrome: histopathological characteristics and aberrant sequence repeats . Pathology International . 59 . 10 . 720–8 . October 2009 . 19788617 . 10.1111/j.1440-1827.2009.02434.x . free .
  25. Woodford MR, Dunn DM, Blanden AR, Capriotti D, Loiselle D, Prodromou C, Panaretou B, Hughes PF, Smith A, Ackerman W, Haystead TA, Loh SN, Bourboulia D, Schmidt LS, Marston Linehan W, Bratslavsky G, Mollapour M . 6 . The FNIP co-chaperones decelerate the Hsp90 chaperone cycle and enhance drug binding . Nature Communications . 7 . 12037 . June 2016 . 27353360 . 4931344 . 10.1038/ncomms12037 . 2016NatCo...712037W .
  26. Baba M, Hong SB, Sharma N, Warren MB, Nickerson ML, Iwamatsu A, Esposito D, Gillette WK, Hopkins RF, Hartley JL, Furihata M, Oishi S, Zhen W, Burke TR, Linehan WM, Schmidt LS, Zbar B . 6 . Folliculin encoded by the BHD gene interacts with a binding protein, FNIP1, and AMPK, and is involved in AMPK and mTOR signaling . Proceedings of the National Academy of Sciences of the United States of America . 103 . 42 . 15552–15557 . October 2006 . 17028174 . 1592464 . 10.1073/pnas.0603781103 . free . 2006PNAS..10315552B .
  27. Takagi Y, Kobayashi T, Shiono M, Wang L, Piao X, Sun G, Zhang D, Abe M, Hagiwara Y, Takahashi K, Hino O . 6 . Interaction of folliculin (Birt-Hogg-Dubé gene product) with a novel Fnip1-like (FnipL/Fnip2) protein . Oncogene . 27 . 40 . 5339–5347 . September 2008 . 18663353 . 10.1038/onc.2008.261 . 9965195 .
  28. Shackelford DB, Shaw RJ . The LKB1-AMPK pathway: metabolism and growth control in tumour suppression . Nature Reviews. Cancer . 9 . 8 . 563–575 . August 2009 . 19629071 . 2756045 . 10.1038/nrc2676 .
  29. Wang L, Kobayashi T, Piao X, Shiono M, Takagi Y, Mineki R, Taka H, Zhang D, Abe M, Sun G, Hagiwara Y, Okimoto K, Matsumoto I, Kouchi M, Hino O . 6 . Serine 62 is a phosphorylation site in folliculin, the Birt-Hogg-Dubé gene product . FEBS Letters . 584 . 1 . 39–43 . January 2010 . 19914239 . 10.1016/j.febslet.2009.11.033 . 20383948 .
  30. Baba M, Furihata M, Hong SB, Tessarollo L, Haines DC, Southon E, Patel V, Igarashi P, Alvord WG, Leighty R, Yao M, Bernardo M, Ileva L, Choyke P, Warren MB, Zbar B, Linehan WM, Schmidt LS . 6 . Kidney-targeted Birt-Hogg-Dube gene inactivation in a mouse model: Erk1/2 and Akt-mTOR activation, cell hyperproliferation, and polycystic kidneys . Journal of the National Cancer Institute . 100 . 2 . 140–54 . January 2008 . 18182616 . 10.1093/jnci/djm288 . 2704336.
  31. Chen J, Futami K, Petillo D, Peng J, Wang P, Knol J, Li Y, Khoo SK, Huang D, Qian CN, Zhao P, Dykema K, Dykyma K, Zhang R, Cao B, Yang XJ, Furge K, Williams BO, Teh BT . 6 . Deficiency of FLCN in mouse kidney led to development of polycystic kidneys and renal neoplasia . PLOS ONE . 3 . 10 . e3581 . 2008 . 18974783 . 10.1371/journal.pone.0003581 . 2570491. 2008PLoSO...3.3581C . free .
  32. Hasumi Y, Baba M, Ajima R, Hasumi H, Valera VA, Klein ME, Haines DC, Merino MJ, Hong SB, Yamaguchi TP, Schmidt LS, Linehan WM . Homozygous loss of BHD causes early embryonic lethality and kidney tumor development with activation of mTORC1 and mTORC2 . Proceedings of the National Academy of Sciences of the United States of America . 106 . 44 . 18722–7 . November 2009 . 19850877 . 10.1073/pnas.0908853106 . 2765925. 2009PNAS..10618722H . free .
  33. Hartman TR, Nicolas E, Klein-Szanto A, Al-Saleem T, Cash TP, Simon MC, Henske EP . The role of the Birt-Hogg-Dubé protein in mTOR activation and renal tumorigenesis . Oncogene . 28 . 13 . 1594–604 . April 2009 . 19234517 . 10.1038/onc.2009.14 . 2664853.
  34. van Slegtenhorst M, Khabibullin D, Hartman TR, Nicolas E, Kruger WD, Henske EP . The Birt-Hogg-Dube and tuberous sclerosis complex homologs have opposing roles in amino acid homeostasis in Schizosaccharomyces pombe . The Journal of Biological Chemistry . 282 . 34 . 24583–90 . August 2007 . 17556368 . 10.1074/jbc.M700857200 . 34442960 . free .
  35. Nookala RK, Langemeyer L, Pacitto A, Ochoa-Montaño B, Donaldson JC, Blaszczyk BK, Chirgadze DY, Barr FA, Bazan JF, Blundell TL . 6 . Crystal structure of folliculin reveals a hidDENN function in genetically inherited renal cancer . Open Biology . 2 . 8 . 120071 . August 2012 . 22977732 . 10.1098/rsob.120071 . 3438538.
  36. Tsun ZY, Bar-Peled L, Chantranupong L, Zoncu R, Wang T, Kim C, Spooner E, Sabatini DM . The folliculin tumor suppressor is a GAP for the RagC/D GTPases that signal amino acid levels to mTORC1 . Molecular Cell . 52 . 4 . 495–505 . November 2013 . 24095279 . 10.1016/j.molcel.2013.09.016 . 3867817.
  37. Bar-Peled L, Sabatini DM . Regulation of mTORC1 by amino acids . Trends in Cell Biology . 24 . 7 . 400–6 . July 2014 . 24698685 . 10.1016/j.tcb.2014.03.003 . 4074565.
  38. Petit CS, Roczniak-Ferguson A, Ferguson SM . Recruitment of folliculin to lysosomes supports the amino acid-dependent activation of Rag GTPases . The Journal of Cell Biology . 202 . 7 . 1107–22 . September 2013 . 24081491 . 10.1083/jcb.201307084 . 3787382.
  39. Péli-Gulli MP, Sardu A, Panchaud N, Raucci S, De Virgilio C . Amino Acids Stimulate TORC1 through Lst4-Lst7, a GTPase-Activating Protein Complex for the Rag Family GTPase Gtr2 . Cell Reports . 13 . 1 . 1–7 . October 2015 . 26387955 . 10.1016/j.celrep.2015.08.059 . free .
  40. Armah HB, Parwani AV . Xp11.2 translocation renal cell carcinoma . Archives of Pathology & Laboratory Medicine . 134 . 1 . 124–9 . January 2010 . 20073616 . 10.5858/2008-0391-RSR.1 .
  41. Hong SB, Oh H, Valera VA, Baba M, Schmidt LS, Linehan WM . Inactivation of the FLCN tumor suppressor gene induces TFE3 transcriptional activity by increasing its nuclear localization . PLOS ONE . 5 . 12 . e15793 . December 2010 . 21209915 . 10.1371/journal.pone.0015793 . 3012117. 2010PLoSO...515793H . free .
  42. Betschinger J, Nichols J, Dietmann S, Corrin PD, Paddison PJ, Smith A . Exit from pluripotency is gated by intracellular redistribution of the bHLH transcription factor Tfe3 . Cell . 153 . 2 . 335–47 . April 2013 . 23582324 . 10.1016/j.cell.2013.03.012 . 3661979.
  43. Klomp JA, Petillo D, Niemi NM, Dykema KJ, Chen J, Yang XJ, Sääf A, Zickert P, Aly M, Bergerheim U, Nordenskjöld M, Gad S, Giraud S, Denoux Y, Yonneau L, Méjean A, Vasiliu V, Richard S, MacKeigan JP, Teh BT, Furge KA . 6 . Birt-Hogg-Dubé renal tumors are genetically distinct from other renal neoplasias and are associated with up-regulation of mitochondrial gene expression . BMC Medical Genomics . 3 . 59 . December 2010 . 21162720 . 10.1186/1755-8794-3-59 . 3012009 . free .
  44. Hasumi H, Baba M, Hasumi Y, Huang Y, Oh H, Hughes RM, Klein ME, Takikita S, Nagashima K, Schmidt LS, Linehan WM . 6 . Regulation of mitochondrial oxidative metabolism by tumor suppressor FLCN . Journal of the National Cancer Institute . 104 . 22 . 1750–64 . November 2012 . 23150719 . 10.1093/jnci/djs418 . 3502196.
  45. Hasumi Y, Baba M, Hasumi H, Huang Y, Lang M, Reindorf R, Oh HB, Sciarretta S, Nagashima K, Haines DC, Schneider MD, Adelstein RS, Schmidt LS, Sadoshima J, Marston Linehan W . 6 . Folliculin (Flcn) inactivation leads to murine cardiac hypertrophy through mTORC1 deregulation . Human Molecular Genetics . 23 . 21 . 5706–19 . November 2014 . 24908670 . 10.1093/hmg/ddu286 . 4189904.
  46. Medvetz DA, Khabibullin D, Hariharan V, Ongusaha PP, Goncharova EA, Schlechter T, Darling TN, Hofmann I, Krymskaya VP, Liao JK, Huang H, Henske EP . Folliculin, the product of the Birt-Hogg-Dube tumor suppressor gene, interacts with the adherens junction protein p0071 to regulate cell-cell adhesion . PLOS ONE . 7 . 11 . e47842 . 2012 . 23139756 . 10.1371/journal.pone.0047842 . 3490959. 2012PLoSO...747842M . free .
  47. Nahorski MS, Seabra L, Straatman-Iwanowska A, Wingenfeld A, Reiman A, Lu X, Klomp JA, Teh BT, Hatzfeld M, Gissen P, Maher ER . 6 . Folliculin interacts with p0071 (plakophilin-4) and deficiency is associated with disordered RhoA signalling, epithelial polarization and cytokinesis . Human Molecular Genetics . 21 . 24 . 5268–79 . December 2012 . 22965878 . 10.1093/hmg/dds378 . 3755511.
  48. Goncharova EA, Goncharov DA, James ML, Atochina-Vasserman EN, Stepanova V, Hong SB, Li H, Gonzales L, Baba M, Linehan WM, Gow AJ, Margulies S, Guttentag S, Schmidt LS, Krymskaya VP . 6 . Folliculin controls lung alveolar enlargement and epithelial cell survival through E-cadherin, LKB1, and AMPK . Cell Reports . 7 . 2 . 412–23 . April 2014 . 24726356 . 10.1016/j.celrep.2014.03.025 . 4034569.
  49. Khabibullin D, Medvetz DA, Pinilla M, Hariharan V, Li C, Hergrueter A, Laucho Contreras M, Zhang E, Parkhitko A, Yu JJ, Owen CA, Huang H, Baron RM, Henske EP . 6 . Folliculin regulates cell-cell adhesion, AMPK, and mTORC1 in a cell-type-specific manner in lung-derived cells . Physiological Reports . 2 . 8 . August 2014 . 25121506 . 10.14814/phy2.12107 . 4246594 . e12107.
  50. Kennedy JC, Khabibullin D, Henske EP . Mechanisms of pulmonary cyst pathogenesis in Birt-Hogg-Dube syndrome: The stretch hypothesis . Seminars in Cell & Developmental Biology . 52 . 47–52 . April 2016 . 26877139 . 10.1016/j.semcdb.2016.02.014 .
  51. Esteban MA, Harten SK, Tran MG, Maxwell PH . Formation of primary cilia in the renal epithelium is regulated by the von Hippel–Lindau tumor suppressor protein . Journal of the American Society of Nephrology . 17 . 7 . 1801–6 . July 2006 . 16775032 . 10.1681/ASN.2006020181 . free .
  52. Hartman TR, Liu D, Zilfou JT, Robb V, Morrison T, Watnick T, Henske EP . The tuberous sclerosis proteins regulate formation of the primary cilium via a rapamycin-insensitive and polycystin 1-independent pathway . Human Molecular Genetics . 18 . 1 . 151–63 . January 2009 . 18845692 . 10.1093/hmg/ddn325 . 2644647.
  53. Luijten MN, Basten SG, Claessens T, Vernooij M, Scott CL, Janssen R, Easton JA, Kamps MA, Vreeburg M, Broers JL, van Geel M, Menko FH, Harbottle RP, Nookala RK, Tee AR, Land SC, Giles RH, Coull BJ, van Steensel MA . Birt-Hogg-Dube syndrome is a novel ciliopathy . Human Molecular Genetics . 22 . 21 . 4383–97 . November 2013 . 23784378 . 10.1093/hmg/ddt288 . 3792695.
  54. Zhong M, Zhao X, Li J, Yuan W, Yan G, Tong M, Guo S, Zhu Y, Jiang Y, Liu Y, Jiang Y . Tumor Suppressor Folliculin Regulates mTORC1 through Primary Cilia . The Journal of Biological Chemistry . 291 . 22 . 11689–97 . May 2016 . 27072130 . 10.1074/jbc.M116.719997 . 4882437. free .
  55. Boehlke C, Kotsis F, Patel V, Braeg S, Voelker H, Bredt S, Beyer T, Janusch H, Hamann C, Gödel M, Müller K, Herbst M, Hornung M, Doerken M, Köttgen M, Nitschke R, Igarashi P, Walz G, Kuehn EW . 6 . Primary cilia regulate mTORC1 activity and cell size through Lkb1 . Nature Cell Biology . 12 . 11 . 1115–22 . November 2010 . 20972424 . 10.1038/ncb2117 . 3390256.
  56. Possik E, Jalali Z, Nouët Y, Yan M, Gingras MC, Schmeisser K, Panaite L, Dupuy F, Kharitidi D, Chotard L, Jones RG, Hall DH, Pause A . Folliculin regulates ampk-dependent autophagy and metabolic stress survival . PLOS Genetics . 10 . 4 . e1004273 . April 2014 . 24763318 . 10.1371/journal.pgen.1004273 . 3998892 . free .
  57. Dunlop EA, Seifan S, Claessens T, Behrends C, Kamps MA, Rozycka E, Kemp AJ, Nookala RK, Blenis J, Coull BJ, Murray JT, van Steensel MA, Wilkinson S, Tee AR . 6 . FLCN, a novel autophagy component, interacts with GABARAP and is regulated by ULK1 phosphorylation . Autophagy . 10 . 10 . 1749–60 . October 2014 . 25126726 . 10.4161/auto.29640 . 4198360.
  58. Bastola P, Stratton Y, Kellner E, Mikhaylova O, Yi Y, Sartor MA, Medvedovic M, Biesiada J, Meller J, Czyzyk-Krzeska MF . Folliculin contributes to VHL tumor suppressing activity in renal cancer through regulation of autophagy . PLOS ONE . 8 . 7 . e70030 . 2013 . 23922894 . 10.1371/journal.pone.0070030 . 3726479. 2013PLoSO...870030B . free .
  59. Cash TP, Gruber JJ, Hartman TR, Henske EP, Simon MC . Loss of the Birt-Hogg-Dubé tumor suppressor results in apoptotic resistance due to aberrant TGFβ-mediated transcription . Oncogene . 30 . 22 . 2534–46 . June 2011 . 21258407 . 10.1038/onc.2010.628 . 3109270.
  60. Yan M, Gingras MC, Dunlop EA, Nouët Y, Dupuy F, Jalali Z, Possik E, Coull BJ, Kharitidi D, Dydensborg AB, Faubert B, Kamps M, Sabourin S, Preston RS, Davies DM, Roughead T, Chotard L, van Steensel MA, Jones R, Tee AR, Pause A . 6 . The tumor suppressor folliculin regulates AMPK-dependent metabolic transformation . The Journal of Clinical Investigation . 124 . 6 . 2640–50 . June 2014 . 24762438 . 10.1172/JCI71749 . 4038567.
  61. Yan M, Audet-Walsh É, Manteghi S, Dufour CR, Walker B, Baba M, St-Pierre J, Giguère V, Pause A . Chronic AMPK activation via loss of FLCN induces functional beige adipose tissue through PGC-1α/ERRα . Genes & Development . 30 . 9 . 1034–46 . May 2016 . 27151976 . 10.1101/gad.281410.116 . 4863735.
  62. Preston RS, Philp A, Claessens T, Gijezen L, Dydensborg AB, Dunlop EA, Harper KT, Brinkhuizen T, Menko FH, Davies DM, Land SC, Pause A, Baar K, van Steensel MA, Tee AR . 6 . Absence of the Birt-Hogg-Dubé gene product is associated with increased hypoxia-inducible factor transcriptional activity and a loss of metabolic flexibility . Oncogene . 30 . 10 . 1159–73 . March 2011 . 21057536 . 10.1038/onc.2010.497 . 3787473.

This article is licensed under the GNU Free Documentation License. It uses material from the Wikipedia article "Folliculin".

Except where otherwise indicated, Everything.Explained.Today is © Copyright 2009-2024, A B Cryer, All Rights Reserved. Cookie policy.